Alkermes plc
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and preventionā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$51.44
Price+7.02%
$3.37
1Y
Price
Market Cap
$8.574b
Mid
Price/Earnings 3y Avg5y Avg
57.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-5.5%
EBITDA Margin-16.9%
Net Profit Margin-43.2%
Free Cash Flow Margin-5.5%
EBITDA Margin-16.9%
Net Profit Margin-43.2%
Free Cash Flow MarginRevenue
$1.562b
+5.9%
1y CAGR-1.9%
3y CAGR+11.0%
5y CAGREarnings
$152.720m
-36.8%
1y CAGR-22.6%
3y CAGR+64.3%
5y CAGREPS
$0.90
-37.1%
1y CAGR-22.6%
3y CAGR+62.2%
5y CAGRBook Value
$1.752b
$4.258b
Assets$2.507b
Liabilities$1.582b
DebtDebt to Assets
37.1%
5.7x
Debt to EBITDAFree Cash Flow
$221.800m
-53.8%
1y CAGR-6.9%
3y CAGR+533.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company